The Oncology Report CHICAGO – The combination of bevacizumab and irinotecan far outshone tenozolomide in delaying disease progression among patients with MGMT-unmethylated glioblastoma, an investigator reported at the annual meeting of the American Society of ...
DailyFinance ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP ( adenosine triphosphate) for ... and more »
GlobeNewswire (press release) Both ADC product candidates involve SN-38, the active metabolite of irinotecan (used to treat metastatic colorectal and other solid cancers), conjugated by the Company's proprietary technology to labetuzumab (anti-CEACAM5 humanized monoclonal ...
PR Web (press release) ... cancer patients using a combination of four drugs called FOLFIRINOX (5-Fluoruoricil, Leucovorin, Oxaliplatin, and Irinotecan ) compared to Gemzar. The FOLFIRINOX regimen showed an increase in overall survival by 63% (11.1 months on FOLFIRINOX vs. and more »
Stockhouse People who received Avastin alone or Avastin plus irinotecan * (chemotherapy) experienced mild to life-threatening side effects including bleeding (occurred in 40 percent of people), nosebleeds (occurred in 26 percent of people), bleeding in the brain ... and more »
Medscape ... for patients with nonmutated forms of the KRAS gene, cetuximab (Erbitux, ImClone Systems Incorporated) appears to be more effective than bevacizumab (Avas...
Business Wire (press release) BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced final data from a randomized, placebo-controlled, double-blind, Phase 2 clinical trial with tivantinib in combination with cetuximab and irinotecan in patients with relapsed or refractory KRAS ... and more »
Business Wire (press release) Pexa-Vec is also being evaluated in a phase 1/2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a phase 2a clinical trial in treatment-refractory kidney cancer patients ... and more »
4-traders (press release) ... drug application to Japan's Ministry of Health, Labor and Welfare (hereafter, MHLW) for an additional indication and dosage for Topotecin® intravenous drip infusion 40 mg and 100 mg ( irinotecan hydrochloride hydrate) for treatment of pancreatic cancer.
GlobeNewswire (press release) Both ADC product candidates involve SN-38, the active metabolite of irinotecan (used to treat metastatic colorectal and other solid cancers), conjugated by the Company's proprietary technology to labetuzumab (anti-CEACAM5 humanized monoclonal ...
